Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT01804790
Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer
- NCT01804790 ↗
- Completed
- UNICANCER
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT01804790 (resectable locally advanced rectal cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT01804790 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Cancer of the Rectum
- Interventions
- mFolfirinox; Radiotherapy 50 Gy; Capecitabine; TME surgery; mFolfox6 or capecitabine
- Arms
- Arm A : Radiotherapy + capecitabine · Active comparator
- Arm B : Chemotherapy then radiochemotherapy · Experimental
- Enrollment
- 461
- Primary outcomes
- disease-free survival
- Sponsor
- UNICANCER
- Start
- Jan 2012
- Primary completion
- Jul 1, 2023
- Results posted
- No
- Registry record
- NCT01804790 · updated Jun 12, 2025
Publications
linked from the registry- Conroy T, Bosset JF, Etienne PL, Rio E, Francois E, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouche O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardiere C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13. PubMed 33862000